Annovis Bio jumps 12% on positive ANVS401 data from Phase 2 Parkinson's disease study

seekingalpha2021-10-05

Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 Parkinson's disease (PD) patients, which found that once-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

beebeeyan
2021-10-05
beebeeyan
amc
- Kiattt:
  K
PanaCota
2021-10-05
PanaCota
Ok
- beebeeyan:
  amc

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1171562230?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-05 21:06","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1171562230","market":"us","top_or_hot":-1,"title":"Annovis Bio jumps 12% on positive ANVS401 data from Phase 2 Parkinson's disease study","media":"seekingalpha","content":"<div>\n<p>Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 Parkinson's disease (PD) patients, which found that once-...</p>\n\n<a href=\"https://seekingalpha.com/news/3748970-annovis-bio-jumps-12-on-positive-anvs401-data-from-phase-2-parkinsons-disease-study\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis Bio jumps 12% on positive ANVS401 data from Phase 2 Parkinson's disease study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis Bio jumps 12% on positive ANVS401 data from Phase 2 Parkinson's disease study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-05 21:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748970-annovis-bio-jumps-12-on-positive-anvs401-data-from-phase-2-parkinsons-disease-study><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 Parkinson's disease (PD) patients, which found that once-...</p>\n\n<a href=\"https://seekingalpha.com/news/3748970-annovis-bio-jumps-12-on-positive-anvs401-data-from-phase-2-parkinsons-disease-study\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANVS","symbol_name":"Annovis Bio, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3748970-annovis-bio-jumps-12-on-positive-anvs401-data-from-phase-2-parkinsons-disease-study","article_id":"1171562230","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171562230","pubTimestamp":1633439209,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANVS":"Annovis Bio, Inc."},"translate_title":"Annovis Bio在2期帕金森病研究的阳性ANVS401数据上跃升12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANVS":0.9},"content_text":"Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 Parkinson's disease (PD) patients, which found that once-daily ANVS401 was superior to placebo in improving motor function.\nThe PD patients were treated with either 0mg, 5mg, 10mg, 20mg, 40mg or 80mg of ANVS401 once daily.\nANVS401 has been found to be well-tolerated and safe with no adverse effects related to treatment observed.\nWhen compared to the placebo group, statistically significant improvements in Wechsler Adult Intelligence Scale (WAIS) coding scores were observed in PD patients taking ANVS401 5mg, 20mg and 80mg once daily, highlighting increased motor-dexterity, as well as speed and accuracy compared to placebo.\nPD patients treated with ANVS401 10mg and 20mg once daily showed statistically significant improvements in the MDS-Unified Parkinson's Disease Rating Scale compared to baseline.\nANVS will request a meeting with the FDA to receive guidance on next steps in clinical development in light of the AD/PD Phase 2 clinical results.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":820772915,"gmtCreate":1633440109618,"gmtModify":1633440143483,"author":{"id":"3581331692871918","authorId":"3581331692871918","name":"beebeeyan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"amc","listText":"amc","text":"amc","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820772915","repostId":1171562230,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6100562,"gmtCreate":1633440557874,"gmtModify":1634721298788,"authorId":3575378956741249,"author":{"id":3575378956741249,"authorId":3575378956741249,"name":"Kiattt","avatar":"https://static.tigerbbs.com/586600416b343f9d9fc7463cf77c2825","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820772915,"type":1,"supId":0,"prevId":0,"content":"<u>K</u>","text":"<u>K</u>","html":"<u>K</u>"}],"langContent":"CN"},{"id":820776559,"gmtCreate":1633440094131,"gmtModify":1633440094806,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820776559","repostId":1171562230,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6100467,"gmtCreate":1633440115129,"gmtModify":1634721307763,"authorId":3581331692871918,"author":{"id":3581331692871918,"authorId":3581331692871918,"name":"beebeeyan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820776559,"type":1,"supId":0,"prevId":0,"content":"am<u><u>c</u></u>","text":"am<u><u>c</u></u>","html":"am<u><u>c</u></u>"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":50,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171562230"}